Boston Scientific CorporationNYSE: BSX
Health Care · Health Care Equipment
$56.75
-1.50%
Vol: 17.8M
Research Digest
Friday, May 1, 2026
Boston Scientific Q1 2026 sales $5.2B (+11.6%); FARAPULSE PFA strong clinical data, J&J initiates head-to-head trial.
Boston Scientific Q1 2026 net sales $5.203B (+11.6% reported, +9.4% operational basis). GAAP net income $1.341B ($0.90 EPS vs $0.45 prior year). Presented FARAPULSE PFA clinical data showing 95.6% PVI durability at two months with no stroke or coronary complications. J&J initiated head-to-head trial comparing Varipulse Pro to BSX Farapulse in up to 466 patients with persistent AFib. FDA issued recall on certain pacemakers with Brady SMR6 software update. Mixed analyst sentiment with Argus lowering PT to $95 from $115.
Previous Market Intelligence
13 daysApr 30Boston Scientific reports Q1 2026 net sales up 11.6% but faces competitive pressures in electrophysiology and ongoing class action litigation.Mixed▶
Boston Scientific posted Q1 2026 net sales of $5.203 billion, up 11.6% on a reported basis and 9.4% operationally YoY. GAAP net income reached $1.341 billion or $0.90 per share, compared to $0.45 a year ago, with adjusted EPS of $0.80 vs $0.75 prior year. However, the company faces multiple headwinds including class action lawsuits related to false statements about the U.S. Electrophysiology segment and competitive pressure from J&J's head-to-head clinical trial comparing pulsed field ablation platforms.
Apr 16Boston Scientific Q1 Earnings April 22; Faces Securities Class Action LawsuitMixed▶
Boston Scientific announced Q1 2026 earnings conference call scheduled for April 22, 2026 at 8:00 a.m. ET with CEO Mike Mahoney and CFO Jon Monson. Stock dropped 17% following Q4 2025 earnings release on February 4, 2026. Portnoy Law Firm announced securities class action on behalf of investors with losses, filing window until May 4, 2026. Company holds 2026 Annual Meeting of Stockholders on April 30, 2026. Recent FDA clearance for Asurys Fluid Management System and proposed $14.5 billion acquisition of Penumbra provide growth catalyst. Stock price $64.37 with 10.15% decline over past month. Citi reaffirmed Buy rating despite legal headwinds.
Apr 15Boston Scientific faces class action lawsuit over electrophysiology demand disclosure; Q1 earnings call April 22.Negative▶
Boston Scientific is dealing with a securities fraud class action lawsuit filed by investors claiming the company misled about U.S. Electrophysiology segment sustainability. Price targets have been mixed: Evercore ISI lowered target to $80 from $96, while Citi and RBC maintained Buy ratings. The stock is down 33.6% year-to-date at $62.88. Q1 earnings conference call scheduled for April 22.
Apr 14Boston Scientific faces securities class action over alleged Electrophysiology segment misstatements; Q1 earnings April 22.Negative▶
Boston Scientific will release Q1 2026 earnings on April 22 with anticipated 6.67% YoY EPS growth. However, institutional investors filed a securities class action alleging materially misleading statements about US Electrophysiology segment sustainability. When slower growth was disclosed on February 4, billions in market cap were erased. Despite clinical wins, investor sentiment remains pressured by legal risks.
Apr 13Boston Scientific shares decline 15% in 30 days on analyst downgrade, EP slowdown concerns, and Penumbra acquisition delays.Negative▶
BSX fell to $61.28, down 15% over past month. Raymond James downgraded citing U.S. electrophysiology slowdowns. CHAMPION AF trial met endpoints for WATCHMAN FLX; FDA cleared Asurys Fluid Management System. $14.5B Penumbra acquisition faces regulatory delays. Organic growth decelerating from 15.8% (2025) to projected 10-11% (2026). Q1 earnings due April 22.
Apr 10Boston Scientific faces securities class action after Q1 earnings miss on electrophysiology segment weakness.Negative▶
Boston Scientific is facing multiple securities class action lawsuits regarding misstatements about the U.S. Electrophysiology segment sustainable growth. The company reported a net income miss and underwhelming guidance for H1 2026. Stock down 9% to $62.29. Price targets cut from multiple analysts. Upcoming Q1 earnings call April 22, 2026.
Apr 9Boston Scientific acquires Penumbra in major deal; receives FDA clearance for new system amid 35% six-month stock decline.Mixed▶
Boston Scientific announced definitive agreement to acquire Penumbra Inc. in a cash and stock transaction for mechanical thrombectomy and neurovascular devices. Also announced agreements to acquire Valencia Technologies (eCoin nerve stimulation) and Nalu Medical (neurostimulation system). Company received FDA 510(k) clearance March 30 for Asurys Fluid Management System. Stock has plunged 35% in six months amid growth concerns, trading near 52-week low of $61.23. Q1 earnings call scheduled for April 22, 2026. Major analysts (Evercore ISI, Needham, RBC, Raymond James, Goldman Sachs) maintain Buy/Outperform ratings despite recent underperformance.
Apr 8Boston Scientific Receives FDA Clearance for Asurys Fluid Management System; WATCHMAN FLX Study Meets EndpointsMixed▶
Boston Scientific received FDA clearance for the Asurys Fluid Management System for urological procedures. The CHAMPION-AF study of WATCHMAN FLX device met all primary and secondary safety and efficacy endpoints, showing superior protection from bleeding versus blood thinners. The company acquired Valencia Technologies, adding eCoin tibial nerve stimulator to compete in urge urinary incontinence market. BSX is down 34.7% YTD trading at $61.86. Evercore ISI lowered price target to $80 from $96 on April 6. Despite litigation concerns, analysts remain cautiously optimistic on product pipeline.
Apr 7Boston Scientific to acquire Penumbra for $14.5B; stock slides 9% on cautious revenue guidance despite FDA approvalsMixed▶
Boston Scientific announced acquisition of Penumbra ($374/share, $14.5B enterprise value) expanding thrombectomy capabilities. WATCHMAN FLX study met all FDA endpoints. Asurys Fluid Management System cleared March 30. However, BSX shares fell 9% to 2-year low of $62.73 on cautious 2026 guidance: 10.5-11.5% reported growth (down from 15.8% in 2025) and adjusted EPS of $3.43-3.49. Evercore ISI lowered PT to $80 from $96. Completed Valencia Technologies and Nalu Medical acquisitions.
Apr 6Boston Scientific completes $14.5B Penumbra acquisition; provides cautious 2026 outlookMixed▶
Boston Scientific announced a $14.5B acquisition of Penumbra in a cash and stock deal valued at $374 per share. The company also acquired Nalu Medical for chronic peripheral nerve pain expansion. Despite Q4 strength, BSX provided modest 2026 guidance: organic revenue growth of 10-11% (down from 15.8% in 2025) and adjusted EPS of $3.43-3.49 versus $3.47 consensus. The stock dropped 9% in premarket on March 30 amid dilution concerns and a recall of its Accolade pacemaker line. The WATCHMAN FLX LAA study met all primary and secondary endpoints. Q1 2026 earnings are due April 22. The Penumbra deal adds significant growth optionality but near-term guidance moderation is weighing on sentiment.
Apr 3Boston Scientific completes Penumbra acquisition for $14.5B and faces shareholder lawsuit over electrophysiology growth claims.Mixed▶
Boston Scientific announced a major acquisition of Penumbra in a cash-and-stock transaction valued at ~$14.5B, expected to close in 2026. FDA cleared Asurys Fluid Management System. However, a securities fraud lawsuit alleges the company overstated sustainability of U.S. electrophysiology growth. Stock down 27.5% YTD. Q1 2026 earnings call scheduled for April 22.
Apr 2Boston Scientific stock down 32% YTD as 2026 guidance disappoints with 10-11% organic growth forecast versus 15.8% in 2025, plus legal/regulatory headwinds.Negative▶
Boston Scientific reported cautious 2026 guidance of 10-11% organic revenue growth, significantly below 2025's 15.8%, causing a 9% single-day decline on March 30. The company is acquiring Penumbra for $14.5B at $374/share and Nalu Medical for chronic pain treatment. Raymond James downgraded to outperform from strong buy, citing slower electrophysiology and Watchman device trends. Boston Scientific Q1 earnings call set for April 22. FDA cleared Asurys fluid management system.
Apr 1Boston Scientific CHAMPION-AF trial met endpoints but showed higher stroke rate vs. NOACs; stock down 34% YTD with Raymond James downgrade.Negative▶
Boston Scientific announced CHAMPION-AF trial results for its Watchman heart implant, which met all endpoints but showed slightly higher ischemic stroke rate versus NOAC drugs. FY2025 net sales reached $20.07 billion (up 19.9% YoY). Raymond James downgrade sparked a 9.4% drop. UBS reiterated Buy with $105 PT.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
| EWEDWARDS | $84.28 | +0.93% | +2.9% | 24.8x | 0.94 | $48.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.